Not a Lexis+ subscriber? Try it out for free.

Experience a New Era in Legal Research with Free Access to Lexis+

Dana-Farber Cancer Inst., Inc. v. Ono Pharm. Co.

United States District Court for the District of Massachusetts

May 17, 2019, Decided; May 17, 2019, Filed

Civil Action No. 15-13443-PBS

Opinion

 [*58]  FINDINGS OF FACT, CONCLUSIONS OF LAW, AND ORDER

Saris, C.J.

TABLE OF CONTENTS

INTRODUCTION

FINDINGS OF FACT

I. Scientific Background

A. The Immune System and Receptor-Ligand Signaling

B. Experimental Methods

II. Discoveries [**2]  of PD-1 and 292

A. Dr. Honjo Discovers the PD-1 Receptor

B. Dr. Honjo Asks for Help Identifying the Ligand for PD-1

and Begins to Collaborate with Dr. Wood in September 1998

C. Dr. Freeman Discovers the 292 Ligand in July 1998

D. Dr. Wood Connects the PD-1/PD-L1 Pathway in September

III. October 25, 1999 Collaboration Meeting in Cambridge

IV. Developments Between the October 1999 and May 2000 Meetings

A. Dr. Freeman and Dr. Honjo Exchange Reagents, and Dr. Wood

and Dr. Honjo Run Experiments Confirming the Inhibitory

Effect of the PD-1/PD-L1 Pathway in November and December

B. Dr. Freeman and Dr. Wood File a Provisional Patent

Application in November 1999

C. Dr. Freeman, Dr. Wood, and Dr. Honjo Draft a Journal

Article on the PD-1/PD-L1 Pathway in March and April 2000

D. Dr. Freeman Conducts Immunohistochemistry ("IHC")

Experiments in the Winter of 2000

E. Dr. Freeman Discovers PD-L2 in the Fall of 1999

F. Dr. Freeman, Dr. Wood, and Dr. Minato Independently

Develop Antibodies Throughout 1999 and 2000

G. Dr. Honjo and Dr. Wood's Meeting in March 2000

H. Dr. Iwai Begins In Vivo Tumor Model Studies in March 2000

V. May 13, 2000 Collaboration Meeting in Seattle

VI. Developments During the Summer of 2000 [**3] 

VII. September 8, 2000 Collaboration Meeting in Cambridge

Read The Full CaseNot a Lexis Advance subscriber? Try it out for free.

Full case includes Shepard's, Headnotes, Legal Analytics from Lex Machina, and more.

379 F. Supp. 3d 53 *; 2019 U.S. Dist. LEXIS 83375 **; 2019 WL 2147092

DANA-FARBER CANCER INSTITUTE, INC., Plaintiff, v. ONO PHARMACEUTICAL CO., LTD.; TASUKU HONJO; E.R. SQUIBB & SONS, L.L.C.; and BRISTOL-MYERS SQUIBB, CO., Defendants.

Subsequent History: Affirmed by Dana-Farber Cancer Inst., Inc. v. Ono Pharm. Co., 2020 U.S. App. LEXIS 21704 (Fed. Cir., July 14, 2020)

Prior History: Dana-Farber Cancer Inst., Inc. v. Ono Pharm. Co., 186 F. Supp. 3d 22, 2016 U.S. Dist. LEXIS 58710 (D. Mass., May 2, 2016)

CORE TERMS

tumor, patents, inventor, collaboration, antibodies, pathway, ligand, cancer, blocking, discovery, invention, receptor, inhibitory, protein, mouse, interaction, bind, inventorship, corroboration, inhibits, scientists, signal, molecule, sequence, anti-PD-1, laboratory, email, vivo, experimental, reagents

Patent Law, Originality, Correction of Inventorship Errors, Joint & Sole Inventorship, Invention Date & Priority, Conception Date, Evidence, Burdens of Proof, Clear & Convincing Proof, Presumptions, Particular Presumptions, Regularity, Infringement Actions, Claim Interpretation, General Overview, Types of Evidence, Testimony, Credibility of Witnesses, Allocation, Burdens of Proof, Claims & Specifications, Claims, Claim Language, Civil Procedure, Defenses, Demurrers & Objections, Affirmative Defenses, Laches